8-KOther Events

ABBOTT LABORATORIES 8-K Report, Corporate Update (Nov 30, 2009)

Filed November 30, 2009For Securities:ABT

Summary

Abbott Laboratories (ABT) has announced a significant development regarding its pharmaceutical product, Tricor® 145 mg, through an 8-K filing dated November 30, 2009. The company, along with patent owner Laboratories Fournier S.A., has entered into a license agreement with Teva Pharmaceuticals USA Inc. This agreement grants Teva specific rights to the intellectual property associated with Tricor® 145 mg, with a staggered effective date. Investors should note that Teva's access to this intellectual property is set to commence no earlier than March 28, 2011. However, the filing also stipulates that under certain conditions, Teva may not gain these rights until as late as July 1, 2012. This delayed market entry for potential generic competition suggests a continued period of market exclusivity for Abbott, which is a crucial factor for revenue and profitability projections of this product line.

Key Highlights

  • 1Abbott Laboratories entered into a license agreement with Teva Pharmaceuticals USA Inc.
  • 2The agreement pertains to the intellectual property rights for Tricor® 145 mg.
  • 3Teva is granted rights to the intellectual property, but with a delayed start date.
  • 4Teva may gain access to the intellectual property no earlier than March 28, 2011.
  • 5Under specific circumstances, Teva's access could be further delayed until July 1, 2012.
  • 6This filing addresses a potential future competitive landscape for Tricor® 145 mg.

Frequently Asked Questions

The main purpose of this 8-K filing is to disclose a license agreement between Abbott Laboratories (and patent owner Laboratories Fournier S.A.) and Teva Pharmaceuticals USA Inc. regarding the intellectual property for Tricor® 145 mg.

Teva Pharmaceuticals can begin using the intellectual property no sooner than March 28, 2011. However, the agreement includes provisions that could delay this start date until July 1, 2012, depending on certain defined circumstances.

This agreement suggests that Abbott Laboratories has secured a defined period of market exclusivity for Tricor® 145 mg, as generic entry by Teva is delayed. This is important for investors as it impacts the projected revenue stream from this product and provides clarity on the competitive timeline.

No, this filing does not indicate an immediate impact on Tricor® 145 mg sales. It pertains to a future licensing agreement and the timeline for Teva Pharmaceuticals USA Inc. to potentially access the intellectual property, which is set for 2011 or 2012.